Author:
Margherita Bertuzzi (UK)
Abstract:
Background: The fungal pathogen Aspergillus fumigatus (Af) affects >3,000,000 individuals annually, with invasive aspergillosis having mortality rates of >50%. Airway Epithelial Cells (AECs), which cover the entire alveolar surface and comprise 24% of all cells in the human lung parenchyma, have immediate, extensive, and likely prolonged contact with Af conidia upon inhalation. We previously demonstrated that AECs provide a potent means of antifungal defense against Af in vivo, and that dysfunctional epithelial antifungal activity in at-risk patients may provide an opportunity for Af to exploit AECs as a safe haven to reside intracellularly. However, the fungal and host factors controlling Af uptake and clearance by AECs are poorly understood.
Methods: To determine how healthy AECs recognise and kill Af and how these processes are dysregulated in disease, we exploit single-cell workflows to perform molecular, transcriptional, and cellular analyses of the Af-AEC interaction in vitro and in vivo.
Results: Using fluorescent auxotrophic pyrG- strains locked at specific morphological stages, we determined morphotype-specific interactions with AECs, whereby swollen conidia locked at 3 and 6 hours of germination are 2-fold more readily internalized than conidia locked at 0 hours. Probing with fluorescent lectins, we identified mannose as a key surface carbohydrate that show a morphotype-specific increase during germination. Supporting this, mannose and the mannose- binding lectin Concanavalin A were able to respectively reduce (by 88%) and abolish (100%) Af internalization. Using a combination of Af mutants, and AEC receptor mutants, we are systematically evaluating morphotype-specific factors on Af surface and characterizing key host receptors for their role in mediating fungal uptake and clearance both healthy and diseased AECs.
Conclusions: Understanding how AECs contribute to antifungal clearance by recognizing morphotype-specific fungal factors is of mayor clinical importance as it could inform the development of much needed novel antifungal therapeutics.
Abstract Number: 58
Conference Year: 2024
Conference abstracts, posters & presentations
-
Title
Author
Year
Number
Poster
-
v
Teclegiorgis Gebremariam [MS]1, Yiyou Gu [PhD]1, Sondus Alkhazraji [PhD]1, Jousha Quran1, Laura K. Najvar [BS]2, Nathan P. Wiederhold [PharmD]2, Thomas F. Patterson [MD]2, Scott G. Filler [MD]1,3, David A. Angulo (MD)4, Ashraf S. Ibrahim [PhD]1,3*,
2024
91
n/a
-
v
Ruta Petraitiene (US)
2024
90
n/a
-
v
Fabio Palmieri (CH), Junier Pilar
2024
89
n/a
-
v
Evelyne Côté (CA)
2024
88
n/a
-
v
Eliane Vanhoffelen (BE)
2024
87
n/a
-
v
Teclegiorgis Gebremariam, Yiyou Gu, Eman Youssef, Sondus Alkhazraji, Joshua Quran, Nathan P. Wiederhold, Ashraf S. Ibrahim
2024
86
n/a
-
v
Thomas Orasch (DE)
2024
85
n/a
-
v
Julien Alex, Katherine González, Gauri Gangapurwala, Antje Vollrath, Zoltán Cseresnyés, Christine Weber, Justyna A. Czaplewska, Stephanie Hoeppener, Carl-Magnus Svensson, Thomas Orasch, Thorsten Heinekamp, Carlos Guerrero-Sánchez, Marc Thilo Figge, Ulrich S. Schubert, Axel A. Brakhage
2024
84
n/a
-
v
Vasireddy Teja, Bibhuti Saha Hod, Soumendranath Haldar (IN)
2024
83
n/a
-
v
Vasireddy Teja, Bibhuti Saha Hod, Soumendranath Haldar (IN)
2024
82
n/a